ArticleInterdisciplinary cardiovascular and thoracic surgery2026
Outcomes of Lung Transplantation From Asphyxiation Donors: Reassessing Hypoxic Injury and Implications for Donation After Circulatory Death.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWith persistent donor shortages limiting lung transplantation (LT), optimizing the use of extended-criteria donors is essential. Asphyxiation (AXP) and donation after circulatory death (DCD) donors both experience hypoxic-ischaemic injury, raising concern for graft performance. We evaluated the long-term outcomes of AXP donor LT and the effect of ex vivo lung perfusion (EVLP) on survival.
methodsAdult recipients (≥18 years) of primary LT (2014-2024) in the United Network for Organ Sharing registry were stratified by donor cause of death: AXP vs non-AXP. Survival was estimated by Kaplan-Meier analysis, and multivariable Cox regression identified factors associated with mortality. Subgroup analyses examined EVLP and DCD vs donation after brain death (DBD) cohorts.
resultsAmong 26 334 LT recipients, 1406 (5.3%) received AXP donor lungs. Asphyxiation donors were more frequently DCD (9.5% vs 6%, P < .001). Ten-year recipient (25.2% vs 27.4%; P = .67) and graft (24.1% vs 26.8%; P = .72) survival were comparable, and AXP status was not independently associated with mortality after adjusting for allocation era (HR 1.01, 95% CI, 0.91-1.11, P = .908). However, EVLP use in AXP lungs correlated with decreased 3-year survival (55.3% vs 74.1%; P = .035). Sensitivity analyses demonstrated significant differences among the 4 donor subgroups (DCD-AXP, DCD non-AXP, DBD-AXP, and DBD non-AXP) on overall comparison (P = .008), with DCD-AXP recipients exhibiting numerically the highest 5-year survival rates.
conclusionsAXP donor lungs provide comparable long-term outcomes, and DCD-AXP grafts do not appear to confer inferior survival. The interaction between AXP and EVLP use warrants further study to refine donor reconditioning strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.